Intratumoral immunocytokine treatment results in enhanced antitumor effects
- 26 April 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 57 (12), 1891-1902
- https://doi.org/10.1007/s00262-008-0519-0
Abstract
Immunocytokines (IC), consisting of tumor-specific monoclonal antibodies fused to the immunostimulatory cytokine interleukin 2 (IL2), exert significant antitumor effects in several murine tumor models. We investigated whether intratumoral (IT) administration of IC provided enhanced antitumor effects against subcutaneous tumors. Three unique ICs (huKS-IL2, hu14.18-IL2, and GcT84.66-IL2) were administered systemically or IT to evaluate their antitumor effects against tumors expressing the appropriate IC-targeted tumor antigens. The effect of IT injection of the primary tumor on a distant tumor was also evaluated. Here, we show that IT injection of IC resulted in enhanced antitumor effects against B16-KSA melanoma, NXS2 neuroblastoma, and human M21 melanoma xenografts when compared to intravenous (IV) IC injection. Resolution of both primary and distant subcutaneous tumors and a tumor-specific memory response were demonstrated following IT treatment in immunocompetent mice bearing NXS2 tumors. The IT effect of huKS-IL2 IC was antigen-specific, enhanced compared to IL2 alone, and dose-dependent. Hu14.18-IL2 also showed greater IT effects than IL2 alone. The antitumor effect of IT IC did not always require T cells since IT IC induced antitumor effects against tumors in both SCID and nude mice. Localization studies using radiolabeled 111In-GcT84.66-IL2 IC confirmed that IT injection resulted in a higher concentration of IC at the tumor site than IV administration. In conclusion, we suggest that IT IC is more effective than IV administration against palpable tumors. Further testing is required to determine how to potentially incorporate IT administration of IC into an antitumor regimen that optimizes local and systemic anticancer therapy.Keywords
This publication has 43 references indexed in Scilit:
- In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophagesJournal of Leukocyte Biology, 2006
- A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology GroupClinical Cancer Research, 2006
- Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma PatientsJournal of Clinical Oncology, 2004
- A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of the Children's Oncology GroupJournal of Immunotherapy, 2004
- Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)Journal of Immunotherapy, 2004
- IN SITU VACCINATION AGAINST A NON-IMMUNOGENIC TUMOUR USING INTRATUMOURAL INJECTIONS OF LIPOSOMAL INTERLEUKIN 2Cytokine, 2001
- Immunocytokines: A Promising Approach to Cancer ImmunotherapyPharmacology & Therapeutics, 1998
- Polyethylene‐glycol‐modified interleukin‐2 is superior to interleukin‐2 in locoregional immunotherapy of established guinea‐pig tumorsInternational Journal of Cancer, 1992
- A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2aCancer Immunology, Immunotherapy, 1992
- Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.The Journal of Experimental Medicine, 1990